
















Variable		N	Hazard ratio	p	
Age at diagnosis (Days)		487		1.00 (1.00, 1.00)	<0.001
Biological Sex	Female	218		Reference	
	Male	269		1.01 (0.82, 1.25)	0.901
Immune Cluster	3	136		Reference	
	1	188		0.98 (0.74, 1.29)	0.872
	2	163		1.54 (1.14, 2.06)	0.004
2021_WHO_Classification	Pediatric-type diffuse low-grade gliomas, NOS	73		Reference	
	Diffuse astrocytoma, MYB- or MYBL1-altered	7		1.47 (0.60, 3.58)	0.396
	Diffuse low-grade glioma, MAPK pathway-altered	134		1.21 (0.85, 1.73)	0.299
	Ganglioglioma	35		1.11 (0.68, 1.80)	0.675
	Glioneuronal and neuronal tumors	5		1.35 (0.47, 3.82)	0.577
	Myxoid glioneuronal tumor	9		1.98 (0.89, 4.37)	0.093
	Pilocytic astrocytoma	203		1.01 (0.72, 1.41)	0.960
	Pleomorphic xanthoastrocytoma	3		2.62 (0.79, 8.65)	0.113
	Subependymal giant cell astrocytoma	18		0.55 (0.23, 1.31)	0.177
			